These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 17341847)
21. The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. Zitzmann K; de Toni E; von Rüden J; Brand S; Göke B; Laubender RP; Auernhammer CJ Endocr Relat Cancer; 2011 Apr; 18(2):277-85. PubMed ID: 21317202 [TBL] [Abstract][Full Text] [Related]
22. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Karreth FA; DeNicola GM; Winter SP; Tuveson DA Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255 [TBL] [Abstract][Full Text] [Related]
23. Focal adhesion kinase, a downstream mediator of Raf-1 signaling, suppresses cellular adhesion, migration, and neuroendocrine markers in BON carcinoid cells. Ning L; Chen H; Kunnimalaiyaan M Mol Cancer Res; 2010 May; 8(5):775-82. PubMed ID: 20407018 [TBL] [Abstract][Full Text] [Related]
24. Neuronal calcium activates a Rap1 and B-Raf signaling pathway via the cyclic adenosine monophosphate-dependent protein kinase. Grewal SS; Horgan AM; York RD; Withers GS; Banker GA; Stork PJ J Biol Chem; 2000 Feb; 275(5):3722-8. PubMed ID: 10652372 [TBL] [Abstract][Full Text] [Related]
25. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Murphy DA; Makonnen S; Lassoued W; Feldman MD; Carter C; Lee WM Am J Pathol; 2006 Nov; 169(5):1875-85. PubMed ID: 17071608 [TBL] [Abstract][Full Text] [Related]
27. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2. Wen-Sheng W Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661 [TBL] [Abstract][Full Text] [Related]
28. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation. Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094 [TBL] [Abstract][Full Text] [Related]
29. Raf: a strategic target for therapeutic development against cancer. Beeram M; Patnaik A; Rowinsky EK J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185 [TBL] [Abstract][Full Text] [Related]
30. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. von Wichert G; Jehle PM; Hoeflich A; Koschnick S; Dralle H; Wolf E; Wiedenmann B; Boehm BO; Adler G; Seufferlein T Cancer Res; 2000 Aug; 60(16):4573-81. PubMed ID: 10969809 [TBL] [Abstract][Full Text] [Related]
31. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Gollob JA; Wilhelm S; Carter C; Kelley SL Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795 [TBL] [Abstract][Full Text] [Related]
32. BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors. Tannapfel A; Vomschloss S; Karhoff D; Markwarth A; Hengge UR; Wittekind C; Arnold R; Hörsch D Am J Clin Pathol; 2005 Feb; 123(2):256-60. PubMed ID: 15842051 [TBL] [Abstract][Full Text] [Related]
33. [Studies on cell signaling immunomodulated murine peritoneal suppressor macrophages: LPS and PMA mediate the activation of RAF-1, MAPK p44 and MAPK p42 and p38 MAPK]. Chang ZL; Lin MQ; Wang MZ; Yao Z Shi Yan Sheng Wu Xue Bao; 1997 Mar; 30(1):73-81. PubMed ID: 10684111 [TBL] [Abstract][Full Text] [Related]
34. The Mystery of Rap1 Suppression of Oncogenic Ras. Nussinov R; Jang H; Zhang M; Tsai CJ; Sablina AA Trends Cancer; 2020 May; 6(5):369-379. PubMed ID: 32249186 [TBL] [Abstract][Full Text] [Related]
35. Elastin peptides activate extracellular signal-regulated kinase 1/2 via a Ras-independent mechanism requiring both p110gamma/Raf-1 and protein kinase A/B-Raf signaling in human skin fibroblasts. Duca L; Lambert E; Debret R; Rothhut B; Blanchevoye C; Delacoux F; Hornebeck W; Martiny L; Debelle L Mol Pharmacol; 2005 Apr; 67(4):1315-24. PubMed ID: 15653554 [TBL] [Abstract][Full Text] [Related]
36. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Adnane L; Trail PA; Taylor I; Wilhelm SM Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355 [TBL] [Abstract][Full Text] [Related]
37. Phosphorylation of Rap1 by cAMP-dependent Protein Kinase (PKA) Creates a Binding Site for KSR to Sustain ERK Activation by cAMP. Takahashi M; Li Y; Dillon TJ; Stork PJ J Biol Chem; 2017 Jan; 292(4):1449-1461. PubMed ID: 28003362 [TBL] [Abstract][Full Text] [Related]
38. Stromal inhibition of megakaryocytic differentiation is associated with blockade of sustained Rap1 activation. Delehanty LL; Mogass M; Gonias SL; Racke FK; Johnstone B; Goldfarb AN Blood; 2003 Mar; 101(5):1744-51. PubMed ID: 12393469 [TBL] [Abstract][Full Text] [Related]
39. Ras-independent activation of ERK signaling via the torso receptor tyrosine kinase is mediated by Rap1. Mishra S; Smolik SM; Forte MA; Stork PJ Curr Biol; 2005 Feb; 15(4):366-70. PubMed ID: 15723799 [TBL] [Abstract][Full Text] [Related]